相似文献
1
Cellular immunotherapies for cancer.癌症的细胞免疫疗法
Oncoimmunology. 2017 May 2;6(5):e1306619. doi: 10.1080/2162402X.2017.1306619. eCollection 2017.
2
Cellular immunotherapy for malignant gliomas.恶性脑胶质瘤的细胞免疫治疗。
Expert Opin Biol Ther. 2016 Oct;16(10):1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29.
3
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.嵌合抗原受体工程：过继细胞免疫治疗进化过程中的正确步骤。
Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419.
4
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.自然杀伤细胞免疫疗法在癌症治疗中的应用。
Front Immunol. 2015 Nov 17;6:578. doi: 10.3389/fimmu.2015.00578. eCollection 2015.
5
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.增强基于癌细胞的免疫疗法的临床可行方法。
Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814.
6
Cellular immunotherapy of cancer: an overview and future directions.癌症的细胞免疫疗法：概述与未来方向。
Immunotherapy. 2017 Jun;9(7):589-606. doi: 10.2217/imt-2016-0086.
7
Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.自然杀伤细胞的病毒和非病毒工程作为新兴的过继性癌症免疫疗法。
J Immunol Res. 2018 Sep 17;2018:4054815. doi: 10.1155/2018/4054815. eCollection 2018.
8
NK Cell-Based Immunotherapies in Cancer.基于自然杀伤细胞的癌症免疫疗法
Immune Netw. 2020 Mar 9;20(2):e14. doi: 10.4110/in.2020.20.e14. eCollection 2020 Apr.
9
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.嵌合抗原受体修饰的自然杀伤细胞治疗胶质母细胞瘤：将固有效应细胞转化为癌症免疫治疗的精准工具。
Front Immunol. 2019 Nov 14;10:2683. doi: 10.3389/fimmu.2019.02683. eCollection 2019.
10
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?传统 1 型树突状细胞对保护性抗肿瘤免疫是否至关重要？以及如何发挥作用？
Front Immunol. 2019 Feb 12;10:9. doi: 10.3389/fimmu.2019.00009. eCollection 2019.
引用本文的文献
1
Prognostic role of long non-coding RNA USP30-AS1 in ovarian cancer: insights into immune cell infiltration in the tumor microenvironment.长非编码 RNA USP30-AS1 在卵巢癌中的预后作用：肿瘤微环境中免疫细胞浸润的见解。
Aging (Albany NY). 2023 Dec 4;15(23):13776-13798. doi: 10.18632/aging.205262.
2
Porous Framework Materials for Bioimaging and Cancer Therapy.多孔框架材料在生物成像和癌症治疗中的应用
Molecules. 2023 Jan 31;28(3):1360. doi: 10.3390/molecules28031360.
3
Expression and prognosis analyses of the fibronectin type-III domain-containing (FNDC) protein family in human cancers: A Review.纤维连接蛋白结构域包含蛋白家族在人类癌症中的表达与预后分析：综述。
Medicine (Baltimore). 2022 Dec 9;101(49):e31854. doi: 10.1097/MD.0000000000031854.
4
Bioengineering tools for probing intracellular events in T lymphocytes.生物工程工具用于探测 T 淋巴细胞内的细胞事件。
WIREs Mech Dis. 2021 Jul;13(4):e1510. doi: 10.1002/wsbm.1510. Epub 2020 Oct 19.
5
Trial watch: dendritic cell vaccination for cancer immunotherapy.试验观察：用于癌症免疫治疗的树突状细胞疫苗接种
Oncoimmunology. 2019 Jul 18;8(11):e1638212. doi: 10.1080/2162402X.2019.1638212. eCollection 2019.
6
Trial watch: Peptide-based vaccines in anticancer therapy.试验观察：基于肽的疫苗在抗癌治疗中的应用
Oncoimmunology. 2018 Sep 6;7(12):e1511506. doi: 10.1080/2162402X.2018.1511506. eCollection 2018.
7
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.试验观察：血液系统肿瘤和实体瘤的溶瘤病毒免疫疗法
Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018.
8
4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12.4Mu 降低肝癌干细胞上的 CD47 表达，并增强白细胞介素-12 诱导的抗肿瘤 T 细胞反应。
Mol Ther. 2018 Dec 5;26(12):2738-2750. doi: 10.1016/j.ymthe.2018.09.012. Epub 2018 Sep 18.
9
In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.同种异体自然杀伤细胞（NK）联合西妥昔单抗原位给药治疗胃肠道癌肝转移：一项I期临床试验。
Oncoimmunology. 2018 Mar 19;7(5):e1424673. doi: 10.1080/2162402X.2018.1424673. eCollection 2018.
10
Imaging activated T cells predicts response to cancer vaccines.影像学激活的 T 细胞可预测癌症疫苗的反应。
J Clin Invest. 2018 Jun 1;128(6):2569-2580. doi: 10.1172/JCI98509. Epub 2018 May 14.
本文引用的文献
1
T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.T 细胞重定向至次要组织相容性抗原可指导肿瘤内 TNFα 的表达，并增强过继细胞疗法治疗实体瘤。
Cancer Res. 2017 Feb 1;77(3):658-671. doi: 10.1158/0008-5472.CAN-16-0725. Epub 2016 Nov 21.
2
A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion.肿瘤浸润性 T 淋巴细胞由于半乳糖凝集素导致的 LFA-1 介导的突触完成缺陷的主要分泌缺陷。
Nat Commun. 2016 Jul 22;7:12242. doi: 10.1038/ncomms12242.
3
Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.黑色素瘤患者中 BDCA1+CD14+ 髓样细胞群体的扩增可能会削弱树突状细胞疫苗的疗效。
Cancer Res. 2016 Aug 1;76(15):4332-46. doi: 10.1158/0008-5472.CAN-15-1695. Epub 2016 Jun 20.
4
Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2.用编码CXCR2的mRNA转染肿瘤浸润性T细胞。
Methods Mol Biol. 2016;1428:261-76. doi: 10.1007/978-1-4939-3625-0_17.
5
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.肿瘤浸润淋巴细胞过继细胞疗法联合改良 IL2 方案治疗转移性黑色素瘤患者的持久完全应答。
Clin Cancer Res. 2016 Aug 1;22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. Epub 2016 Mar 22.
6
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.对黑色素瘤患者外周血中新抗原特异性淋巴细胞的前瞻性鉴定。
Nat Med. 2016 Apr;22(4):433-8. doi: 10.1038/nm.4051. Epub 2016 Feb 22.
7
In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity.细胞毒性T细胞的体内杀伤能力有限，涉及动态相互作用和T细胞协同作用。
Immunity. 2016 Feb 16;44(2):233-45. doi: 10.1016/j.immuni.2016.01.010. Epub 2016 Feb 9.
8
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.原发性髓系树突状细胞疫苗接种转移性黑色素瘤患者的有效临床应答。
Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28.
9
Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.活化并扩增的自然杀伤细胞以NKG2D-NKG2DL依赖的方式靶向骨肉瘤肿瘤起始细胞。
Cancer Lett. 2015 Nov 1;368(1):54-63. doi: 10.1016/j.canlet.2015.07.042. Epub 2015 Aug 11.
10
Adoptive T-cell therapy for cancer: The era of engineered T cells.过继性细胞疗法治疗癌症：工程化 T 细胞的时代。
Eur J Immunol. 2015 Sep;45(9):2457-69. doi: 10.1002/eji.201545552. Epub 2015 Aug 21.
Zotero 插件